BioMedPartners

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, focuses on the research, design, and development of protein-drug conjugates by integrating proprietary technologies with disease-specific biology. The company aims to transform the therapeutic landscape by creating innovative antibody-drug conjugates (ADCs) that enhance treatment outcomes for patients. Tubulis is dedicated to identifying new protein-drug combinations for various therapeutic applications, thereby expanding the potential of ADCs in addressing unmet medical needs.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Scenic Biotech B.V., founded in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at the genetic level. The company focuses on identifying and harnessing disease suppressing genes, which serve as potential drug targets. By creating innovative therapies that target these genetic suppressors, Scenic Biotech aims to unlock new treatment possibilities for patients suffering from severe diseases.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor designed to target a critical microRNA that regulates harmful changes in the heart resulting from stress or injury. Cardior Pharmaceuticals is positioned as a planned academic spin-off, emphasizing innovative approaches to address significant cardiovascular health challenges.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, focuses on the research, design, and development of protein-drug conjugates by integrating proprietary technologies with disease-specific biology. The company aims to transform the therapeutic landscape by creating innovative antibody-drug conjugates (ADCs) that enhance treatment outcomes for patients. Tubulis is dedicated to identifying new protein-drug combinations for various therapeutic applications, thereby expanding the potential of ADCs in addressing unmet medical needs.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

Azafaros B.V. is a Netherlands-based company focused on developing therapeutic agents for the treatment of rare metabolic disorders, specifically lysosomal storage disorders (LSDs). The company specializes in the oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the metabolism of glycosphingolipids and are designed to have a dual mode of action that can potentially improve patient outcomes. Through its research and development efforts, Azafaros seeks to provide effective treatments that can significantly enhance the lives of those affected by these severe inherited diseases.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.

Miracor Medical is a medical device company that specializes in developing solutions for severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company focuses on the PiCSO Impulse System, a pressure-controlled intermittent coronary sinus occlusion device. This system is designed to assist cardiac surgeons in treating patients with myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. By improving microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size and enhance cardiac function, potentially lowering the risk of heart failure following acute myocardial infarction.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.

Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor designed to target a critical microRNA that regulates harmful changes in the heart resulting from stress or injury. Cardior Pharmaceuticals is positioned as a planned academic spin-off, emphasizing innovative approaches to address significant cardiovascular health challenges.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.

Miracor Medical is a medical device company that specializes in developing solutions for severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company focuses on the PiCSO Impulse System, a pressure-controlled intermittent coronary sinus occlusion device. This system is designed to assist cardiac surgeons in treating patients with myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. By improving microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size and enhance cardiac function, potentially lowering the risk of heart failure following acute myocardial infarction.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

Miracor Medical is a medical device company that specializes in developing solutions for severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company focuses on the PiCSO Impulse System, a pressure-controlled intermittent coronary sinus occlusion device. This system is designed to assist cardiac surgeons in treating patients with myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. By improving microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size and enhance cardiac function, potentially lowering the risk of heart failure following acute myocardial infarction.

Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

AYOXXA Biosystems GmbH is a biotechnology company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in life science tools, particularly through its proprietary technology platform for multiplexed protein analysis. The company has developed an innovative biochip technology that enables the simultaneous measurement of multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's platform utilizes an in-situ encoded bead array, facilitating the identification and quantification of proteins and biomolecular analytes. This advanced approach to biomarker analysis positions AYOXXA at the forefront of diagnostic technology, allowing for comprehensive testing in a single assay.

Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.

ImevaX GmbH is a biopharmaceutical company based in Munich, Germany, established in 2014. The company specializes in developing targeted vaccines to address chronic and nosocomial infections, with a particular focus on immune evasion factors employed by various pathogens. Its lead candidate, IMX 101, is designed to combat Helicobacter pylori, a bacterium responsible for stomach ulcers and gastric cancer in humans. ImevaX's research highlights the role of specific bacterial factors that enable H. pylori to evade the host immune response, prompting further investigation into similar mechanisms in other infectious pathogens. The company's efforts aim to enhance treatment options and improve health outcomes for patients suffering from these persistent infections.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.

Middle Peak Medical is a privately held medical device company focused on the development and commercialization of a novel technology to treat mitral valve disease. The company’s proprietary device has application in both percutaneous catheter-based intervention, and in minimally invasive or open-heart cardiac surgery.

SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.

Vaximm specializes in developing active immunotherapies, specifically oral T-cell vaccines, for cancer patients. The company's lead product candidate, VXM01, aims to target the tumor vasculature, a critical component for tumor growth beyond microscopic size. Vaximm's innovative approach utilizes modified attenuated bacteria as first-in-class oral T-cell activators, allowing for flexible targeting of various cancer-related antigens. Preclinical studies have demonstrated significant anti-tumor activity, and Vaximm is poised to advance into human clinical trials, marking a significant step in offering advanced treatment options for cancer patients.

SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Evolva Holding SA is a biotechnology company based in Switzerland that specializes in discovering, developing, and commercializing innovative ingredients for various sectors, including food, nutrition, personal healthcare, and agriculture. Founded in 2004, the company leverages a proprietary synthetic biology technology platform to create high-quality ingredients that mirror the properties of natural products while eliminating their drawbacks. Evolva's product portfolio includes branded ingredients like Veri-te Resveratrol, used for age-related health, and EverSweet Stevia, a natural sweetener. Additionally, the company offers Nootkashield for pest control, EveNootkatone for flavor and fragrance applications, and EveValencene, a citrus flavoring. Evolva serves diverse markets, including nutrition, flavors and fragrances, animal health, personal care, and pharmaceuticals, both developing its own products and collaborating with other industry players.

Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.

Evolva Holding SA is a biotechnology company based in Switzerland that specializes in discovering, developing, and commercializing innovative ingredients for various sectors, including food, nutrition, personal healthcare, and agriculture. Founded in 2004, the company leverages a proprietary synthetic biology technology platform to create high-quality ingredients that mirror the properties of natural products while eliminating their drawbacks. Evolva's product portfolio includes branded ingredients like Veri-te Resveratrol, used for age-related health, and EverSweet Stevia, a natural sweetener. Additionally, the company offers Nootkashield for pest control, EveNootkatone for flavor and fragrance applications, and EveValencene, a citrus flavoring. Evolva serves diverse markets, including nutrition, flavors and fragrances, animal health, personal care, and pharmaceuticals, both developing its own products and collaborating with other industry players.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of innovative anti-infectives aimed at women's health. Founded in 2008, the company offers products such as FemiFect, an antibiotic designed to treat infections associated with vaginitis caused by bacteria, fungi, and protozoa, and SPK-601, which targets human papillomavirus (HPV) and herpes simplex virus (HSV). Lumavita markets its products through various distributors, positioning itself within the expanding biopharmaceutical sector in Switzerland. The company was previously known as Shogoo Pharmaceuticals, AG before rebranding in December 2007 and operates as a subsidiary of Shogoo Pharmaceuticals KK.

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly

Idiag is a specialist in interfacing research & development with sales and marketing. A central business aim is to convert innovative ideas on medical technology into products ready to market. Therefore Idiag offers to Universities and Innovation Centres, to take over final development, production and marketing for their unused medical product potential. Furthermore Idiag offers to manufacturer of high quality supplementing products, to act as reseller. Idiag then uses its existing resources, networks and excellence for market penetration and sales, within Switzerland and Germany.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

EyeSense AG develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. They make blood glucose control easier and pain-free through innovative monitoring devices.

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system.

Dolthera GmbH is a biopharmaceutical company that is developing an innovative class of nucleic-acid-based anti-inflammatory drugs. These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors are all directed against biologically validated targets in major chronic diseases with high unmet medical need. With this business concept and the underlying patent-protected technologies, AVONTEC won in 2003 the prestigious German Founders Award that is backed by McKinsey & Company. Initially, the Company has chosen to focus its patented technology on chronic inflammatory respiratory system and skin diseases. AVONTEC currently has five programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease and autoimmune disease under development. All these indications represent areas with high unmet medical need and strong commercial potential.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies for patients with heart valve diseases, particularly aortic valve stenosis. The company focuses on enhancing patient care and safety by providing simple and accurate solutions for heart valve replacement. Its proprietary Acurate Aortic Valve Replacement System features a distinctive self-positioning design, which facilitates easy implant positioning and alignment, thereby improving the overall ease of use for healthcare providers. Through its advanced transcatheter aortic valve implantation devices, Symetis aims to address severe cardiac valve conditions and enhance treatment options within the healthcare industry.

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

CareX SA is a biopharmaceutical company that develops novel treatments for metabolic and immune system disorders which includes diabetes and obesity. The company focuses on metabolic syndrome, a cluster of inter-related disorders of the body’s metabolism, including high blood pressure, high insulin levels, excess body weight, and abnormal cholesterol levels, that exposes individuals to the development of type 2 diabetes, heart diseases, and strokes. CareX SA is a France-based company that was founded in 2001 and the company was acquired by 7TM Pharma on May 24, 2006.

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

Thommen Medical is a medical device company that specializes in the development, production, and sale of dental implants branded as SPI (Swiss Precision Implant). The company focuses on creating innovative and precisely designed implant systems that enhance patient comfort during surgical procedures and ensure long-term stability of the implants. Thommen Medical also offers biomaterial solutions for bone and tissue regeneration, collaborating with leading scientific and dental clinicians to improve the effectiveness and usability of its products. Through its commitment to design excellence and innovation, Thommen Medical aims to achieve optimal success for its clients in the field of dental implants.